ASSA ABLOY´s divestiture of CEDES in Switzerland to capiton AG completed

– ASSA ABLOY has closed the sale of its sensor technology business CEDES in Switzerland to capiton AG.

PR Newswire

STOCKHOLM, Nov. 12, 2020 /PRNewswire/ — CEDES is a leading sensor technology company in the elevator and door industry. CEDES was established in 1986 and has some 320 employees. The company is headquartered in Landquart, Switzerland. Sales in 2019 amounted to about 51 MEUR.

The transaction will have a neutral effect on ASSA ABLOY’s operating margin.

The divestiture will be de-consolidated from ASSA ABLOY as of November 2020.
 

For more information, please contact:

Nico Delvaux, President and CEO
tel. no: +46 8 506 485 82
Erik Pieder, CFO and Executive Vice President
tel. no: +46 8 506 485 72 
Björn Tibell, Head of Investor Relation
tel. no: +46 70 275 67 68
 

 

About ASSA ABLOY

The ASSA ABLOY Group is the global leader in access solutions. The Group operates worldwide with 49,000 employees and sales of SEK 94 billion. The Group has leading positions in areas such as efficient door openings, trusted identities and entrance automation. ASSA ABLOY’s innovations enable safe, secure and convenient access to physical and digital places. Every day, we help billions of people experience a more open world.

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/assa-abloy/r/assa-abloy-s-divestiture-of-cedes-in-switzerland-to-capiton-ag-completed,c3235550

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/assa-abloys-divestiture-of-cedes-in-switzerland-to-capiton-ag-completed-301171624.html

SOURCE ASSA ABLOY

VAPORESSO Sponsored ‘Modfather Vapes’ East Lancashire Hospice Charity Night

PR Newswire

SHENZHEN, China, Nov. 12, 2020 /PRNewswire/ — On Friday 30th Oct. 2020, an internationally renowned vaping brand, VAPORESSO, sponsored a charity auction night held by local vaping store, Modfather Vapes, in honor of East Lancashire Hospice. The event was held via livestream on the Modfather Vapes’ official Facebook page and featured a number of interesting challenges and an auctioning off of vaping equipment in order to raise money to provide care and financial support to people in need.

“The money raised for the hospice will go towards helping many people and their families. We are a company that prides itself on giving back to our community and we look forward to doing it again. We hope, in this way, we can help out those in need,” the owner of Modfather Vapes said.

According to the feedback received by the hosting team, the event was very well-received. People love to help others, and this was an ideal way for them to show their kindness whilst also receiving vaping devices at a discounted price. The live show lasted for 7 hours and was attended by more than 2,000 people who made over 2600+ comments. The event raised a significant amount of funds, which had been donated to the East Lancashire Hospice.

As the main event sponsor, VAPORESSO fully supported Modfather Vapes in their hosting of the event and offered to provide the most updated vaping products for auction in the charity sale. The night was a great success and Modfather Vapes have decided to frequently host similar livestream shows on their official Facebook page to raise funds for the other needy institutions.

Owned by global vaping R&D giant and the vaping industry’s first publicly listed company, SMOORE International, VAPORESSO has inherited the company’s sense of responsibility. VAPORESSO shows great passion for making contributions to society, not only through its innovative and high-quality vaping products but also by giving back to communities in need. During the pandemic, VAPORESSO utilized its POWERSHOP channel to help international partners and local stores in the UK get through the testing times.

Regardless of industry or company, this year is destined to be an unusual year all round. Only with a strong sense of social responsibility and a willingness to support each other, can we overcome these difficulties together.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vaporesso-sponsored-modfather-vapes-east-lancashire-hospice-charity-night-301171616.html

SOURCE VAPORESSO

Veeco Announces Exchange Transaction to Retire $125 Million of Its 2.70% Convertible Senior Notes Due 2023

PLAINVIEW, N.Y., Nov. 12, 2020 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (“Veeco”) (NASDAQ: VECO) today announced that it has entered into a privately negotiated exchange agreement under which it will retire $125.0 million in aggregate principal amount of Veeco’s outstanding 2.70% Convertible Senior Notes due 2023 (the “Original Notes”) in exchange for the issuance of $132.5 million in aggregate principal amount of Veeco’s new 3.50% Convertible Senior Exchange Notes due 2025 (the “New Notes”) and a cash payment to the holder in the amount of $1.1 million in respect of accrued and unpaid interest on the Original Notes to be exchanged. Following the exchange transaction, $131.7 million in aggregate principal amount of the Original Notes will remain outstanding with the terms unchanged.

The New Notes will mature on January 15, 2025 and will pay interest semiannually at a rate of 3.50% per year. The New Notes have an initial conversion rate of 41.6667 shares of Veeco’s common stock per $1,000 original principal amount of New Notes (equivalent to a conversion price of approximately $24.00 per share), subject to adjustment in certain events. The initial conversion price represents an approximately 58.6% premium over the closing sale price of Veeco’s common stock on November 11, 2020. Conversions of the New Notes will be settled in cash, shares of Veeco’s common stock or a combination thereof, at Veeco’s election.

The holder of the New Notes may convert all or a portion of its notes at its option at any time prior to the close of business on the business day immediately preceding October 15, 2024, only upon the satisfaction of certain conditions and during certain time periods. On or after October 15, 2024 until the close of business on the second scheduled trading day immediately preceding January 15, 2025, the holder may convert its New Notes at any time, without condition.

Veeco may be required to repurchase for cash the New Notes upon the occurrence of a fundamental change (as defined in the indenture governing the New Notes) at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. In addition, upon the occurrence of certain corporate events, the conversion rate on the New Notes will increase.

The New Notes will not be redeemable by Veeco prior to January 15, 2023. On or after January 15, 2023, Veeco may redeem for cash all or any portion of the New Notes if the last reported sale price of Veeco’s common stock equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the trading day of such period) ending on, and including, the trading day immediately preceding the date on which Veeco provides notice of redemption at a redemption price equal to 100% of the principal amount of the New Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date (subject to certain limited exceptions).

Veeco anticipates that the closing of the exchange transaction will occur on or about November 17, 2020, subject to customary closing conditions.

Neither the New Notes, nor any shares of Veeco’s common stock issuable upon conversion of the New Notes, have been, nor will be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and, unless so registered, such securities may not be offered or sold absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.



No Solicitation



This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such jurisdiction.



About Veeco



Veeco is an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, and single wafer etch & clean technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets it serves.



Forward-looking Statements



To the extent that this news release discusses expectations or otherwise makes statements about the future, such statements are forward-looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include Veeco’s ability to close the transaction described in this news release on the terms and within the time anticipated and other risks discussed in the Risk Factors, Business Description and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of Veeco’s Annual Report on Form 10-K for the year ended December 31, 2019, in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of Veeco’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, and in Veeco’s Current Reports on Form 8-K and press releases. Veeco does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances after the date of such statements.

Veeco Contacts:      
Investors: Anthony Bencivenga (516) 252-1438 [email protected]
Media: Kevin Long (516) 714-3978 [email protected]  

Gold Fields Limited: Operational update for the quarter ended 30 September 2020

PR Newswire

JOHANNESBURG, Nov. 12, 2020 /PRNewswire/ — Gold Fields Limited (NYSE: GFI) (JSE: GFI) remains in a strong financial position. During Q3 2020, there was a further decrease in the net debt balance (including leases) to US$1,159m at 30 September 2020 from US$1,239m at 30 June 2020, after taking into account the interim dividend payment of US$85m. This implies a net debt to EBITDA of 0.68x, compared to 0.84x at end June 2020. The net debt balance (excluding leases) decreased to US$796m from US$876m at the end of June 2020.

Full results are available on the company website:

www.goldfields.com

Enquiries

Investors
Avishkar Nagaser
Tel:  +27 11 562-9775
Mobile:  +27 82 312 8692
Email : [email protected]

Thomas Mengel

Tel:  +27 11 562 9849
Mobile:  +27 72 493 5170
Email:  [email protected]

Media

Sven Lunsche
Tel:  +27 11 562-9763
Mobile:  +27 83 260 9279
Email :  [email protected]

Notes to editors

About Gold Fields

Gold Fields is a globally diversified gold producer with nine operating mines in Australia, Peru, South Africa and West Africa (including the Asanko JV), as well as one project in Chile. We have total attributable annual gold-equivalent production of 2.2Moz, attributable gold-equivalent Mineral Reserves of 51.3Moz and Mineral Resources of 115.7Moz. Our shares are listed on the Johannesburg Stock Exchange (JSE) and our American depositary shares trade on the New York Stock Exchange (NYSE).

Sponsor: J.P. Morgan Equities South Africa (Pty) Ltd

 

Cision View original content:http://www.prnewswire.com/news-releases/gold-fields-limited-operational-update-for-the-quarter-ended-30-september-2020-301171610.html

SOURCE Gold Fields Limited

GVC sets out a clear strategy for sustainability, growth and innovation

PR Newswire

LONDON, Nov. 12, 2020 /PRNewswire/ — GVC Holdings PLC (LSE: GVC), the global sports-betting and gaming group whose brands include Ladbrokes, Coral, bwin, Sportingbet, partypoker and BetMGM, is today setting out ambitious plans for the future under its two core strategic pillars of sustainability and growth.

These plans will be driven by the Group’s leading proprietary technology and supported by a range of strategic initiatives, launched today. They include a new corporate identity, a commitment to operating in 100% regulated markets, and new technology-driven protection for customers.

To reflect the Group’s ambition to be the world leader in sports betting and gaming entertainment, GVC is today announcing that, subject to shareholder approval, it will be renamed as Entain plc.  

“Today marks an exciting new chapter for the Group, and an important step forward in achieving our ambition of being the world leader in sports betting and gaming,” said Shay Segev, Chief Executive. “Under our new corporate identity, we will continue to use our unique technology platform to grow in both existing and new markets, innovate, reach new audiences, enhance the customer experience, and provide industry-leading levels of player protection.

We are absolutely committed to pursuing the highest standards of corporate governance, to providing outstanding career development opportunities for our colleagues, and to supporting the communities in which we operate.”




Sustainability Charter Launched


The Group underpinned its commitment to raising standards in responsible gaming with the launch of a new Sustainability Charter today, committing to:  

  • An exclusive focus on regulated markets: a commitment that, by the end of 2023, 100% of the Group’s revenue will come from markets that are nationally regulated – with 99% from regulated or regulating markets by the end of 2020
  • Continuing to lead on responsible gambling: launching the Advanced Responsibility & Care (“ARC”) programme, which uses proprietary technology to further enhance player protection through additional checks as well as improved monitoring and interventions
  • Embedding responsible gambling into our remuneration policy
  • Pursuing the highest standards of corporate governance
  • Investing in people and local communities with the launch of the Entain Foundation, which is committed to donating £100 million over the next five years to provide further support to the international communities in which we operate. In the UK this includes our new Pitching In programme, to support grass roots sports and sports people.


Growth: four key drivers

We have a range of exciting growth opportunities that can significantly increase the scale of the Group over the next three to five years.  These opportunities are based on four strategic imperatives:

  1. Leadership in the US: we have a clear ambition to be the leading operator in the US through BetMGM, our joint venture with MGM Resorts.
  2. Grow our core markets: we have achieved a huge amount in our existing markets, but there is still substantial headroom for further growth.
  3. Enter new markets: we see significant opportunities for expansion into new regulated markets through organic opportunities as well as M&A.
  4. Expand to new audiences: new technology-enabled forms of entertainment are constantly emerging, and we intend to be at the forefront of capturing them.  For instance, eSports and digital gaming are becoming the hub for a rapidly growing audience out of which are evolving new betting markets, and we see significant potential for us in this area.

For further details, please visit: https://gvc-plc.com/news/

About GVC Holdings PLC

GVC Holdings PLC (LSE:GVC) is a FTSE100 company and is one of the world’s largest sports-betting and gaming groups, operating both online and in the retail sector. The Group owns a comprehensive portfolio of established brands; Sports Brands include bwin, Coral, Crystalbet, Eurobet, Ladbrokes, Neds and Sportingbet; Gaming Brands include CasinoClub, Foxy Bingo, Gala, Gioco Digitale, partypoker and PartyCasino. The Group owns proprietary technology across all of its core product verticals and in addition to its B2C operations provides services to a number of third-party customers on a B2B basis. The Group has also entered into a joint-venture with MGM Resorts to capitalise on the sports-betting and gaming opportunity in the US. The Group is tax resident in the UK with licenses in more than 20 countries, across five continents.

For more information see the Group’s website: www.gvc-plc.com 

Cision View original content:http://www.prnewswire.com/news-releases/gvc-sets-out-a-clear-strategy-for-sustainability-growth-and-innovation-301171354.html

SOURCE GVC Holdings plc

Ultimovacs Announces Third Quarter 2020 Result Presentation

Ultimovacs Announces Third Quarter 2020 Result Presentation

OSLO, Norway–(BUSINESS WIRE)–Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), a pharmaceutical company developing novel immunotherapies against cancer, announces its third quarter 2020 results today. A presentation by the Company’s management team will take place today on a webcast at 09:00 CEST.

The presentation can be followed as a live webcast, accessible directly through this link or through the link displayed under Reports and Presentations in the investor section of Ultimovacs’ corporate website www.ultimovacs.com.

Highlights for the third quarter of 2020:

  • In the INITIUM trial, a total of twelve patients have been enrolled as per reporting date (compared to three patients reported in the previous quarterly report). INITIUM is a randomized, multi-center Phase II trial evaluating UV1 as a treatment for first-line patients with metastatic malignant melanoma.
  • In the NIPU trial, a total of six patients have been enrolled as per reporting date (compared to four patients reported in the previous quarterly report). NIPU is a randomized, multi-center Phase II trial in which UV1 is investigated as a second-line treatment in mesothelioma.
  • The Covid-19 situation has so far had fairly limited impact regarding site openings and patient inclusion in the Phase II clinical trials. The longer-term effect of the pandemic on the biotech industry and the general ability to conduct clinical trials is still uncertain.
  • In the fully enrolled US-based Phase I trial in malignant melanoma, positive topline results from the first cohort of 20 patients were announced in September 2020. The results confirm achievement of the primary endpoints of safety and tolerability and indicate initial signs of clinical response; the 12-month Overall Survival (OS) rate was 85% and median Progression Free Survival (mPFS) was not reached after 12 months.
  • Five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer was reported in October 2020. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit. At the five-year landmark, the OS rate was 33% and mPFS was 10.7 months. (Post-period event)
  • In May 2020, Ultimovacs announced a collaboration with a non-specified big pharma company and a leading European oncology clinical trial group to evaluate UV1 in a third Phase II clinical trial. As communicated in September 2020, finalization of the agreement and announcement of the collaboration is expected during the fourth quarter of 2020.
  • The regulatory approval is now in place to start the Phase I TENDU trial. This trial will investigate a prostate cancer specific vaccine based on the TET technology. The first patient is expected to be enrolled in the first quarter of 2021.
  • Total operating expenses amounted to MNOK 31.1 in Q3-20 and MNOK 98.6 YTD. Cash flow from operations was MNOK -29.6 in Q3-20. Total cash and cash equivalents were reduced by MNOK 29.2 during Q3-20, amounting to MNOK 453.5 as per 30 September 2020.

The full report and presentation are also available under Reports and Presentations in the investor section of Ultimovacs’ corporate website www.ultimovacs.com.

About Ultimovacs

Ultimovacs’ UV1 universal cancer vaccine candidate leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumor’s growth and its microenvironment. By directing the immune system to hTERT antigens that are present in over 80% of all cancers, UV1 drives CD4 helper T cells to the tumor with the goal of activating an immune system cascade to increase anti-tumor responses. Ultimovacs’ strategy is to clinically demonstrate UV1’s impact in a range of cancers and in several immunotherapy combinations while expanding our pipeline of cancer vaccine therapies, convinced that a universal approach may be the key to achieving better outcomes for patients.

For further information, please visit www.ultimovacs.com

Carlos de Sousa, CEO

Email: [email protected]

Phone: +47 908 92507

Hans Vassgård Eid, CFO

Email: [email protected]

Phone: +47 482 48632

KEYWORDS: Norway Europe

INDUSTRY KEYWORDS: Pharmaceutical Health Oncology Clinical Trials

MEDIA:

Logo
Logo

Caledonia Mining Corporation Plc: Notification of relevant change to significant shareholder

ST HELIER, Jersey, Nov. 12, 2020 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”) (NYSE AMERICAN: CMCL; AIM: CMCL) announces that it received notification on November 11, 2020, from BlackRock, Inc., which is a “significant shareholder” of the Company as defined by the AIM Rules for Companies, that it has increased its interest in the Company and on November 10, 2020 crossed a particular threshold for notification of its holdings in the Company. A copy of the notification is below.

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached
ii
:
Caledonia Mining Corporation Plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights  
Other (please specify)iii:  
3. Details of person subject to the notification obligation
iv
Name BlackRock, Inc.
City and country of registered office (if applicable) Wilmington, DE, USA
4. Full name of shareholder(s) (if different from 3.)v
Name  
City and country of registered office (if applicable)  
5. Date on which the threshold was crossed or reached
vi
:
10/11/2020
6.
Date on which issuer notified (DD/MM/YYYY):
11/11/2020
7. Total positions of person(s) subject to the notification obligation
  % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached 5.07%   0.47%   5.55%   12,118,823
Position of previous notification (if applicable) 4.80%   0.64%   5.45%    

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
viii
A: Voting rights attached to shares
Class/type of

shares

ISIN code (if possible)
Number of voting rights
ix
% of voting rights
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
JE00BF0XVB15   615,577   5.07%  
         
         
SUBTOTAL 8. A 615,577 5.07%  
 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration

date
x
Exercise/

Conversion Period
xi
Number of voting rights that may be acquired if the instrument is

exercised/converted.
% of voting rights
Securities Lending     25,200 0.20%  
         
         
    SUBTOTAL 8. B 1 25,200 0.20%  
 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration

date
x
Exercise/

Conversion Period
xi
Physical or cash

settlement
xii
Number of voting rights % of voting rights
CFD     Cash 32,901 0.27%  
           
           
      SUBTOTAL 8.B.2 32,901 0.27%  
 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii  
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) X
Name
xv
% of voting rights if it equals
or is higher than the
notifiable threshold
% of voting rights through
financial instruments if it equals or is
higher than the notifiable threshold



Total of both if it equals or is
higher than the notifiable
threshold



See Attachment      
 
10. In case of proxy voting, please identify:
Name of the proxy holder  
The number and % of voting rights held  
The date until which the voting rights will be held  
 
11. Additional information
xvi

BlackRock Regulatory Threshold Reporting Team

James Michael

020 7743 3650

Place of completion 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
Date of completion 11 November, 2020



Section 9 Attachment

Name
xv
% of voting rights if it equals
or is higher than the
notifiable threshold
% of voting rights
through financial instruments
if it equals or is higher than
the notifiable threshold
Total of both if it equals
or is higher than the
notifiable threshold
BlackRock, Inc.      
BlackRock Holdco 2, Inc.      
BlackRock Financial Management, Inc.      
BlackRock Holdco 4, LLC      
BlackRock Holdco 6, LLC      
BlackRock Delaware Holdings Inc.      
BlackRock Institutional Trust Company, National Association      
       
BlackRock, Inc.      
BlackRock Holdco 2, Inc.      
BlackRock Financial Management, Inc.      
BlackRock International Holdings, Inc.      
BR Jersey International Holdings L.P.      
BlackRock (Singapore) Holdco Pte. Ltd.      
BlackRock HK Holdco Limited      
BlackRock Lux Finco S.a.r.l.      
BlackRock Japan Holdings GK      
BlackRock Japan Co., Ltd.      
       
BlackRock, Inc.      
Trident Merger, LLC      
BlackRock Investment Management, LLC      
       
BlackRock, Inc.      
BlackRock Holdco 2, Inc.      
BlackRock Financial Management, Inc.      
BlackRock International Holdings, Inc.      
BR Jersey International Holdings L.P.      
BlackRock Holdco 3, LLC      
BlackRock Canada Holdings LP      
BlackRock Canada Holdings ULC      
BlackRock Asset Management Canada Limited      
       
BlackRock, Inc.      
BlackRock Holdco 2, Inc.      
BlackRock Financial Management, Inc.      
BlackRock Holdco 4, LLC      
BlackRock Holdco 6, LLC      
BlackRock Delaware Holdings Inc.      
BlackRock Fund Advisors      
       
BlackRock, Inc.      
BlackRock Holdco 2, Inc.      
BlackRock Financial Management, Inc.      
       
BlackRock, Inc.      
BlackRock Holdco 2, Inc.      
BlackRock Financial Management, Inc.      
BlackRock Capital Holdings, Inc.      
BlackRock Advisors, LLC      
       

For further information please contact:

Caledonia Mining Corporation Plc

Mark Learmonth
Camilla Horsfall

Tel: +44 1534 679 800
Tel: +44 7817841 793
   
WH Ireland (Nomad & Broker)

Adrian Hadden/James Sinclair-Ford

Tel: +44 20 7220 1751
   
Blytheweigh

Tim Blythe/Megan Ray  

Tel: +44 207 138 3204
   
3PPB

Patrick Chidley
Paul Durham

Tel: +1 917 991 7701
Tel: +1 203 940 2538

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

Etrion Releases Third Quarter 2020 Results

GENEVA, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) — Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), an independent renewable power producer, released today its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three and nine months ended September 30, 2020.

Q3-20 HIGHLIGHTS

Operational

  • Etrion produced 17.0 Gigawatt-hours (“GWh”) of electricity from the Company’s 57-megawatt (“MW”) portfolio comprising 11 solar power plant sites in Japan. Production was in line with forecast but 7.2% below the same period in 2019 due to lower solar irradiation.
  • Construction of the 45 MW Niigata solar project in central Japan is approximately 60% complete with estimated connection to the electricity grid in the fourth quarter of 2021.
  • As of today, the Company has not been adversely affected by COVID-19. The Company has implemented very rigorous guidelines to ensure the wellbeing of its employees while at the same time maintaining minimal business disruptions.

Financial

  • On October 23, 2020, the Company completed the sale of its interest in the Mie 60 MW solar project and received a total of ¥3.4 billion (approximately US$32.2 million) and a development fee of JPY 300 million (approximately US$2.8 million). On October 6, 2020, the Company also received a payment of ¥700 million (approximately US$6.6 million) as reimbursement of advances given to the Mie 60 MW solar project developer, including ¥64 million (approximately US$0.6 million) as interest. In aggregate, Etrion received a total of JPY 4.4 billion (approximately US$41.6 million) on this Mie 60 MW final agreement. USD equivalents were calculated using the actual transaction date exchange rate.
  • The Company engaged Mitsubishi UFJ Morgan Stanley Securities Co., Ltd (“MUMSS”) as financial advisor to assist with the potential sale of the Company’s 57-megawatt operating solar portfolio and its 45-megawatt solar park under construction in Japan.  As a result, management has concluded that as of September 30, 2020, the Japanese solar assets and the entire Solar Segment has met the definition of assets held-for-sale and discontinued operation as per IFRS 5 and prepared its financial reporting accordingly.
  • Etrion’s consolidated revenues from the Japanese discontinued operation were US$6.0 million, 5.4% below the same period in 2019 due to lower solar irradiation.
  • Etrion’s solar segment EBITDA from the Japanese discontinued operation was US$4.8 million, 9.9% lower relative to the same period in 2019. The optimization of the Japanese corporate structure and renegotiation of the O&M contracts partially offset the impact of lower solar irradiation levels compared to the same period in 2019.
  • Etrion’s consolidated EBITDA from continuing operations was US$31.7 million, significantly higher relative to the same period in 2019 due to the sale of the Mie 60 MW solar project.
  • Etrion closed the third quarter of 2020 with an unrestricted cash balance of US$5.5 million held at the corporate level and working capital of US$4.2 million, after excluding the Japanese assets-held-for sale.

Corporate

  • As mentioned above, the Company engaged MUMSS as financial advisor to assist with the potential sale of the Company’s 57-megawatt operating solar portfolio and its 45-megawatt solar park under construction in Japan. Management anticipates receiving one or more binding offers by end of the year. Depending on the offers received, the company will determine whether to proceed to close a sale by the end of the first quarter in 2021, subject to the negotiation of final agreements and the receipt of any required shareholders and regulatory approvals.

Board Update

Garrett Soden will be stepping down from the Board of Directors by the end of the year to comply with industry corporate governance guidelines regarding the maximum number of non-executive director appointments per individual. Aksel Azrak, Chairman of the Board commented “On behalf of the Board members I want to take this opportunity to thank Garrett for his invaluable leadership and contributions as a board member for the past 7 years.”

Management Comments

Marco A. Northland, the Company’s Chief Executive Officer, commented, “We are delighted to have completed the sale of our interest in the Mie project.  On the operational side, our solar plants continue to deliver steady revenues and EBITDA with positive results. On the corporate side, we are making significant progress on the sale process of our Japanese portfolio which has raised strong institutional demand. I am confident we will receive attractive offers for these best-in-class assets.”

FINANCIAL SUMMARY      
  Three months ended Nine months ended


 
US$ thousands (unless otherwise stated) Q3-20 Q3-19 Q3-20 Q3-19  
Electricity production (MWh)1 17,028 18,359 50,031 53,235  
         
Financial performance from continuing operations
 
       
EBITDA 31,734 944 30,383 36  
Net income (loss) 26,818 1,626 23,808 (1,239 )
         
Financial performance from discontinued operations
 
       
Revenue 6,011 6,356 17,437 18,277  
EBITDA 4,757 5,278 13,858 14,061  
Net income 1,212 1,616 3,255 2,800  
         
         
Financial position     Sep 20 Dec 19  
Unrestricted cash at parent level     5,468 10,596  
Restricted cash at project level     112,786  
Working capital     4,151 109,655  
Consolidated net debt on a cash basis     34,206 193,143  
Corporate net debt on a cash basis     34,206 27,201  
Assets-held-for sale, net     20,633  
 
1  MWh = Megawatt-hour

Operations and Finance Update call

A conference call webcast to present the Company’s third quarter 2020 Operations and Finance update will be held on Thursday, November 12, 2020, at 10:00 a.m. Eastern Standard Time (EST) / 4:00 p.m. Central European Time (CET).

Dial-in details:
North America: +1-647-788-4919 / Toll Free: +1-877-291-4570 / Sweden Toll Free: 02-079-4343
Conference ID: 5675576

Webcast:
A webcast will be available at https://www.webcaster4.com/Webcast/Page/1297/33373

The Operations and Finance update call presentation and the Company’s condensed consolidated interim financial statements for the three and nine months ended September 30, 2020, as well as the related documents, will be available on the Company’s website (www.etrion.com)
  
A replay of the telephone conference will be available until November 12, 2021.

Replay dial-in details:
North America: +1-416-621-4642 / Toll Free: +1-800-585-8367 
Passcode for replay: 5675576

About Etrion 

Etrion Corporation is an independent power producer that develops, builds, owns and operates utility-scale solar power generation plants. The Company owns and operates 57 MW of solar capacity and owns the 45 MW Niigata project under construction, all in Japan. The Company is listed on the Toronto Stock Exchange in Canada and the NASDAQ OMX Stockholm exchange in Sweden under ticker symbol “ETX”. Etrion’s largest shareholder is the Lundin family, which owns approximately 36% of the Company’s shares directly and through various trusts.

For additional information, please visit the Company’s website at www.etrion.com or contact:

Christian Lacueva – Chief Financial Officer 
Telephone: +41 (22) 715 20 90
  
Note: The capacity of power plants in this release is described in approximate megawatts on a direct current (“DC”) basis, also referred to as megawatt-peak (“MWp”).

Etrion discloses the information provided herein pursuant to the Swedish Securities Market Act. The information was submitted for publication at 8:05 a.m. CET on November 12, 2020.

Non-IFRS Measures:

This press release includes non-IFRS measures not defined under IFRS, specifically earnings before interest, taxes, depreciation and amortization (“EBITDA”) and Adjusted operating cash flow. Non-IFRS measures have no standardized meaning prescribed under IFRS and therefore such measures may not be comparable with those used by other companies.  EBITDA is a useful metric to quantify the Company’s ability to generate cash before extraordinary and non-cash accounting transactions recognized in the financial statements. In addition, EBITDA is useful to analyze and compare profitability between companies and industries because it eliminates the effects of financing and accounting policy decisions. The most comparable IFRS measure to EBITDA is net income (loss). In addition, adjusted operating cash flow is used by investors to compare cash flows from operating activities without the effects of certain volatile items that can positively or negatively affect changes in working capital and are viewed as not directly related to a company’s operating performance. The most comparable IFRS measure to adjusted operating cash flow is cash flow used in operations. Refer to Etrion’s MD&A for the three and nine months ended September 30, 2020, for a reconciliation of EBITDA and adjusted operating cash flow reported during the period.

Forward-Looking Information: 

This press release contains certain “forward-looking information”. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements relating to the Company’s proposed sale of its Japanese solar assets and the construction and operation of the Niigata project) constitute forward-looking information. This forward-looking information reflects the current expectations or beliefs of the Company based on information currently available to the Company as well as certain assumptions including, without limitation, the ability of the Company to complete the sale of the Japanese assets or, if such sale does not proceed, to execute on its development projects in Japan on economic terms and in a timely manner. Forward-looking information is subject to a number of significant risks and uncertainties and other factors that may cause the actual results of the Company to differ materially from those discussed in the forward-looking information, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Factors that could cause actual results or events to differ materially from current expectations include, but are not limited to, the risk that the Company may not be able to complete the sale of the Japanese assets, the Company’s solar projects may not produce electricity or generate revenues and earnings at the levels expected, the risk that the Company may not be able to obtain all applicable permits for the development of projects in Japan and the associated project financing required for the development of such projects on economic terms, uncertainties with respect to the potential impact of the current COVID-19 pandemic on the Company’s operations and the risk of unforeseen delays in the development and construction of its projects. Reference is also made to the risk factors disclosed under the heading “Risk factors” in the Company’s AIF for the year ended December 31, 2019 which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com.

Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein.

CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference

PR Newswire

MONMOUTH JUNCTION, N.J., Nov. 12, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 and meet with investors in 1×1 meetings throughout the day.  For European investors, please contact your Jefferies representative to assist with scheduling.



Jefferies Virtual London Healthcare Conference




When:
 Tuesday, November 17, 2020 from 2:40PM-3:10PM GMT (9:40AM-10:10AM EST)
Webcast: Jefferies London Presentation Webcast Link

A live webcast of the presentation will be available at the above webcast link.  An archived replay of the webcast will be available for 90 days following the event.

About CytoSorbents Corporation (
NASDAQ: CTSO
)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 110,000 human treatments to date.  CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery.  CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.  CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RGC™, HemoDefend-BGA™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.    For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, including statements regarding our expectations about our cash runway, the advancement of our trials, our plans to initiate new trials, our goals to develop and commercialize CytoSorb and the timing thereof, the potential impact of COVID-19 on our operations and milestones,  and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on

Facebook

 and

Twitter

Cytosorbents Contact:

Amy Vogel

Investor Relations
732-398-5394
[email protected]

Investor Relations Contact:

Jeremy Feffer

LifeSci Advisors
917-749-1494
[email protected]

Public Relations Contact:

Eric Kim

Rubenstein Public Relations
212-805-3055
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference-301171575.html

SOURCE CytoSorbents Corporation

NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy

NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy

  • Positive new data from two (2) pre-clinical presentations delivered at The Society for the Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting:
    • Modulation of TCR Repertoire by Radiotherapy-activated NBTXR3 nanoparticles
      • NBTXR3 activated by radiation therapy produced a strong abscopal effect without a checkpoint inhibitor combination
      • NBTXR3 activated by radiation therapy stimulated adaptive antitumor immunity
      • NBTXR3 activated by radiation therapy increased TCR repertoire diversity in treated tumors compared to radiation therapy alone
    • NBTXR3 Nanoparticle with Immunoradiation Improves Survival and Generates Long-term Anti-tumor Memory in an anti-PD-1 resistant Murine Lung Cancer Model
      • The combination of NBTXR3 plus high dose and low dose radiation (RadScopal™) with anti-PD-1 and anti-CTLA-4 significantly improved the control of both the primary and secondary tumors, extended survival, and reduced lung metastases in an anti-PD-1 resistant lung cancer model
      • NBTXR3 plus RadScopal™ plus checkpoint inhibition promoted anti-tumor response at both molecular and cellular levels
      • NBTXR3 plus RadScopal™ plus checkpoint inhibition produced long-term anti-tumor memory
  • In addition to early efficacy data from the Nanobiotix phase I study evaluating NBTXR3 activated by radiation therapy in combination with anti-PD-1, these results further support the continued acceleration of development for NBTXR3 in immunotherapy

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–NANOBOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo pre-clinical data from two (2) studies at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting. One ePoster presentation was delivered by Nanobiotix and one oral presentation was delivered by The University of Texas MD Anderson Cancer Center (MD Anderson).

Historically, data has shown that radiation therapy can modulate the immune system; however, clinical evidence of distant tumor control and sustained antitumor immunity is rare. As such, there is an opportunity for new treatment solutions with the potential to prime a strong anti-tumor response. If validated, this benefit could improve treatment outcomes for patients receiving radiation therapy alone and could also be combined with immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA to improve response rates and survival outcomes.

NBTXR3 is a potentially first-in-class radioenhancer that is administered one time, directly into the tumor. When activated by radiation therapy, the product candidate is designed to increase the energy deposit within the tumor without increasing the deposit in surrounding healthy tissues. This physical, universal mode of action leads to an increased tumor-killing effect along with adaptive immune response.

Modulation of TCR Repertoire by Radiotherapy-activated NBTXR3 Nanoparticles

Audrey Darmon, Ping Zhang, Sébastien Paris

Abstract ID: 582

In this study, immunocompetent mice were injected in both flanks with colon carcinoma cells. Intratumoral injection of NBTXR3 or of a 5% glucose solution was administered to the right flank tumors at 25% of baseline tumor volume. The right flank tumors were then irradiated, and the left flank tumors remained untreated. To evaluate the role of CD8+ T cell infiltrates in tumor control and abscopal effect, the CD8+ T cells were depleted in some mice treated with NBTXR3.

Results show similar control of the treated tumor in both the NBTXR3 activated by radiation therapy and glucose plus radiation therapy groups, but only NBTXR3 activated by radiation therapy produced an abscopal effect. Depletion of CD8+ T cells completely abolished the abscopal effect, suggesting that CD8+ T cells drive the abscopal effect induced by NBTXR3 activated by radiation therapy.

TCR diversity analysis of NBTXR3 activated by only a 3x4Gy dose of radiation therapy indicated that that more TCR diversity can be found in tumors treated with NBTXR3 than with radiation therapy alone. Additionally, a significant different in TCR diversity was observed between treated and untreated tumors in the NBTXR3 group, while no significant difference was observed in the group that received radiation therapy alone.

NBTXR3 Nanoparticle with Immunoradiation Improves Survival and Generates Long-term Anti-tumor Memory in an anti-PD1 Resistant Murine Lung Cancer Model

Yun Hu, Sébastien Paris, Hampartsoum Barsoumian, Chike Osita Abana, Saumil Gandhi, Quynh-Nhu Nguyen, Maria Angelica Cortez, James W. Welsh

Abstract ID: 200

Although a previous study showed that treatment with high dose radiation and NBTXR3 on primary tumors in combination with systemic anti-PD-1 was able to significantly improve abscopal effect in a murine metastatic lung cancer model, most of the mice eventually died due to the growth of secondary tumors. This new study intended to evaluate the use of NBTXR3 in the primary tumor, high dose radiation therapy in the primary tumor and low dose radiation therapy in the secondary tumor (RadScopal™), and checkpoint inhibition in the form of anti-PD-1 and anti-CTLA-4 to achieve complete control of both primary and second tumors in mice.

All mice in all groups except the group receiving NBTXR3, RadScopal™, and checkpoint inhibition in combination died due to the growth of either the primary tumor or the secondary tumor. In the NBTXR3 plus RadScopal™ plus checkpoint inhibition group, both primary and secondary tumors were eliminated in 50% of mice. No tumor growth was observed in these mice after metastatic lung cancer cells were re-introduced to the body.

These data show that the combination of NBTXR3, RadScopal™, and immunotherapy was observed to significantly improve the control of both the primary and secondary tumors, extend survival, and reduce lung metastases in an anti-PD-1 resistant lung cancer model. Furthermore, this treatment combination was observed to promote anti-tumor response at both molecular and cellular levels, and to produce long-term anti-tumor immune memory.

***

About NBTXR3

NBTXR3 is a novel, potentially first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The primary mode of action (MoA) of NBTXR3 is designed to generate increased cellular destruction when activated by radiation therapy without increasing damage to healthy tissues. Subsequently, this cellular destruction also triggers an adaptive immune response.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Nanobiotix

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

[email protected]

Investor Relations Department

Ricky Bhajun

Senior Manager, Investor Relations

+33 (0)1 79 97 29 99

[email protected]

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0)6 64 79 97 51

[email protected]

KEYWORDS: Europe United States North America France Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo